Aktitropil (phenotropil) [phenylpiracetam] fonturacetam 30 pills 100 mg

Instructions for Aktitropil (phenotropil) [phenylpiracetam] fonturacetam 30 pills 100 mg

Description Aktitropil

flat cylindrical tablets from white to white with a yellowish or brown shade of color with risk on one side and bevel, allowed marbling.

Active substances
Fonturacetam
Release Form

Tablets
Composition
Active ingredient: Fonturacetam - 118.0 mg. Auxiliary substances: Microcrystalline cellulose 101 - 18.0 mg Povidone K-17 (polyvinylpyrrolidone low molecular weight K-17) - 40.0 mg Giprolose (hydroxypropyl cellulose) - 20.0 mg Sodium hydrocarbonate - 20.0 mg Stearic acid - 2.0 mg.

Pharmacodynamics Aktitropil

this drug consists of its ability to exert a pronounced antiamnestic effect and directly activate the integrative activity of the brain. The drug promotes memory consolidation, increases concentration and mental activity, facilitates learning, and speeds up information transfer between brain hemispheres. It also improves the resistance of brain tissue to hypoxia and toxic effects, has anticonvulsant and anxiolytic effects, and regulates activation and inhibition processes in the central nervous system. In addition, this drug has a positive effect on metabolic processes and blood circulation in the brain, activates redox processes and increases the energy potential of the body by using glucose. Improvement of regional blood flow in ischemic regions of the brain is also observed. This drug increases norepinephrine, dopamine, and serotonin levels in the brain, does not affect gamma-aminobutyric acid (GABA) levels, and does not bind to either GABA or GABA receptors. Its action does not noticeably affect the brain's spontaneous bioelectric activity, breathing, and cardiovascular system. The drug has no pronounced diuretic effect, and its course administration shows anorexigenic activity. The stimulating effect of said preparation is mainly manifested in the ability thereof to produce a moderately pronounced effect on motor reactions, to increase the physical efficiency and the pronounced antagonism to the cataleptic effect of antipsychotic drugs. It also weakens the sleep-inducing effects of ethanol and hexenal. The predominant psychostimulatory effect of this drug is in the ideal sphere. Its moderate psychostimulatory effect is combined with anxiolytic activity, improves mood, and has some analgesic effect, raising the threshold for pain sensitivity. The preparation also has an adaptogenic effect, manifested in increasing the resistance of the body to stress in conditions of excessive mental and physical exertion, fatigue, hypokinesia and immobilization, as well as at low temperatures. While taking it, there is an improvement in vision, manifested in an increase in sharpness, brightness and fields of vision. It also improves blood flow to the lower extremities and stimulates antibody production in response to antigen administration, suggesting its immune-stimulating properties. However, it does not promote immediate-type hypersensitivity and does not alter the allergic inflammatory skin reaction caused by injection of foreign protein. Course use of this drug does not indicate the development of drug dependence, tolerance or "withdrawal syndrome". Its action manifests itself with a single dose, which is important when using the drug in extreme conditions. It has no teratogenic, mutagenic, carcinogenic or embryotoxic properties. Its toxicity is low and lethal dose in an acute trial is 800 mg/kg.

Indication Aktitropil

• Various diseases of the central nervous system (CNS), especially associated with vascular and brain metabolism disorders.
• Intoxication, especially in post-traumatic conditions and chronic cerebrovascular insufficiency, accompanied by deterioration of intellectual and memory
• functions, reduced motor activity.
• Neurotic conditions manifesting as lethargy, fatigue, reduced psychomotor activity, disturbance of attention and memory.
• Disruptions in the learning process.
• Obesity of constitutional origin.
• Prevention of hypoxia, increase resistance to stress, correction of the functional state of the body in the conditions of professional activity to prevent fatigue and
• improve performance.
• Chronic alcoholism to reduce asthenic and intellectual memory disorders.

Method of application and dose Aktitropil:

- Take in, immediately after the meal.
- Dose and duration of treatment should be determined by the doctor. Doses vary depending on the person’s condition.
- The average single dose is 150 mg (100 to 250 mg), the average daily dose is 250 mg (200 to 300 mg). The maximum allowable daily dose is 750 mg.
- It is recommended to take daily dose up to 100 mg once in the morning. If the dose exceeds 100 mg, it should be divided into 2 doses.
- Duration of treatment can vary from 2 weeks to 3 months, on average 30 days. If necessary, the course can be repeated in 1 month.
- For better performance it is recommended to take 100-200 mg once in the morning for 2 weeks (for athletes - 3 days).
- Recommended treatment duration for patients with constitutional-nutritional obesity is 30 to 60 days at a dose of 100 to 200 mg once a day (morning). It is not recommended to take the drug after 15:00 hours.